JP Morgan Chase
ELEV

JP Morgan Chase’s Elevation Oncology ELEV Stock Holding History

JP Morgan Chase’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,207
Closed -$1.91K – 7475
2025
Q2 		$1.91K Sell
5,207
-60,545
-92% -$20.2K ﹤0.01% 6546
2025
Q1 		$17K Sell
65,752
-114,623
-64% -$65.4K ﹤0.01% 6199
2024
Q4 		$101K Buy
180,375
+119,041
+194% +$70.3K ﹤0.01% 5751
2024
Q3 		$36.8K Buy
61,334
+39,101
+176% +$58K ﹤0.01% 6083
2024
Q2 		$60K Sell
22,233
-114,976
-84% -$433K ﹤0.01% 5778
2024
Q1 		$704K Buy
137,209
+136,968
+56,833% +$444K ﹤0.01% 4573
2023
Q4 		$129 Sell
241
-9,734
-98% -$5.15K ﹤0.01% 7096
2023
Q3 		$6.61K Sell
9,975
-5,162
-34% -$5.22K ﹤0.01% 6331
2023
Q2 		$23K Sell
15,137
-7,210
-32% -$19K ﹤0.01% 5895
2023
Q1 		$42K Buy
22,347
+18,107
+427% +$23.4K ﹤0.01% 5765
2022
Q4 		$4K Buy
+4,240
New +$4.3K ﹤0.01% 6194

Other funds holding ELEV

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

JP Morgan Chase's ELEV Position: Q3 2025 in Review

JP Morgan Chase sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 5,207 shares — an estimated $1.91K sold.

JP Morgan Chase first reported a position in ELEV in Q4 2022 and held it in 11 quarters. The position peaked at $704K in Q1 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

  • JP Morgan Chase reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 5,207 Elevation Oncology shares in Q3 2025, an estimated $1.91K.
  • JP Morgan Chase first reported a position in Elevation Oncology in Q4 2022 and held it in 11 quarters.
  • JP Morgan Chase's Elevation Oncology position peaked at $704K in Q1 2024.
  • 1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.